OXB confirms partnership with Aura Biosciences

Summary by AI BETAClose X

Oxford Biomedica confirms a manufacturing and supply partnership with Aura Biosciences to support Aura’s lead VDC candidate belzupacap sarotalocan through Phase 3 and potential future commercial supply; OXB has initiated technical transfer to prepare for process performance qualification (PPQ) and commercial production, using its process and analytical development site in Bedford, MA and its FDA-approved commercial-scale viral vector facility in Durham, NC to enable late-stage manufacturing readiness and potential regulatory filings and commercialisation.

Disclaimer*

UK 100

Latest directors dealings